Prof. Ruth Shalgi-Harsina | Sackler Faculty of Medicine
Posttraumatic Growth in Breast Cancer Survivors: Constructive and Illusory Aspects - Pat‐Horenczyk - 2015 - Journal of Traumatic Stress - Wiley Online Library
References in First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised ...
Posttraumatic Growth in Breast Cancer Survivors: Constructive and Illusory Aspects - Pat‐Horenczyk - 2015 - Journal of Traumatic Stress - Wiley Online Library
More Data on COVID-19 Vaccination and Cancer | Cancer Today
COVID-fighting antibodies last 4+ months in 87% of cancer patients: Israeli MDs | The Times of Israel
Leadership – CTG-Pharma
First-of-its-kind study in Israel finds that cancer patients are safe for COVID-19 vaccines - EJP
Pharmaceuticals | Free Full-Text | Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy
Kimberly Lynn Blackwell, MD | medicine.duke.edu
Transnational cancer research lab | Felsenstein Medical Research Center
Transnational cancer research lab | Felsenstein Medical Research Center
Study: COVID-19 shots shown effective in cancer patients up to 4 months later - UPI.com
Cancers | Special Issue : Hepatobiliary Cancers
Patients with cancer achieve response to messenger RNA COVID-19 vaccine
Study: COVID-19 shots shown effective in cancer patients up to 4 months later - UPI.com
COVID vaccine effective for 90% of cancer patients, Israeli study finds | The Times of Israel
Joelle Hallak - Associate Director, HEOR Real World Evidence (RWE) Analytics - AbbVie | LinkedIn
Exclusive program launched for medical industry leaders - Globes
Past Seminars - Health Care Management
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology
Oncotype DX test predicts chemotherapy benefit
Matthew L. Meyerson, MD, PhD - DF/HCC
